Crinetics Pharmaceuticals (CRNX) Q3 2025 earnings summary

Executive summary

• PALSONIFY (paltusotine) launched in the U.S. after FDA approval for acromegaly, showing strong early commercial momentum, broad prescriber engagement, and positive reimbursement trends.

• Deep pipeline includes late-stage programs for carcinoid syndrome, congenital adrenal hyperplasia (CAH), ACTH-dependent Cushing's syndrome, and neuroendocrine tumors, with five clinical trials advancing.

• Multiple commercial and clinical catalysts expected over the next 24+ months, including key readouts, regulatory milestones, and expanded commercialization efforts.

• Cash runway projected into 2029, supporting commercialization and pipeline milestones.

• European review ongoing with potential EMA decision in H1 2026.

Financial highlights

• Q3 2025 revenue was $0.1 million, all from licensing agreements; no product revenue recognized in Q3 due to timing of approval.

• Research and development expenses were $90.5 million in Q3 2025, up from $80.3 million in Q2 and $61.9 million in Q3 2024, reflecting increased clinical activity.

• Selling, general, and administrative expenses rose to $52.3 million in Q3 2025, up from $49.8 million in Q2 and $25.9 million in Q3 2024, driven by launch investments.

• Net loss for Q3 2025 was $130.1 million, up 69% year-over-year; net loss per share was $1.38.

• Cash, cash equivalents, and investments totaled $1.1 billion as of September 30, 2025.

Outlook and guidance

• Maintains 2025 net cash used in operations guidance of $340–$370 million.

• Cash runway expected to last into 2029, supporting commercialization and pipeline development.

• Launch metrics, including revenue and patient starts, to be provided after a full quarter in Q1 2026.

• Multiple late-stage clinical milestones anticipated in Q4 2025 and early 2026, including Phase 3 trial initiations and data readouts.

• Expects to initiate pediatric and additional adult trials for atumelnant and new studies for CRN09682 in late 2025 and 2026.